Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)
Yoshihiko Sakata, Shinya Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Ryota Shibaki, Asuka Okada, Hiroshi Kobe, Hirotaka Matsumoto, Takashi Yokoi, Yuki Sato, Takeshi Uenami, Go Saito, Yoko Tsukita, Megumi Inaba, Hideki Ikeda, Daisuke Arai, Hirotaka Maruyama, Satoshi Hara, Shinsuke Tsumura, Jun Morinaga, Takuro Sakagami
Topics & Concepts
Hazard ratioMedicineInternal medicineInterquartile rangeOsimertinibGastroenterologyConfidence intervalLung cancerOncologyRetrospective cohort studyProgression-free survivalEpidermal growth factor receptorCancerChemotherapyErlotinibLung Cancer Treatments and MutationsInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisLung Cancer Diagnosis and Treatment